4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Black Diamond Therapeutics, Inc. (BDTX) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 21 employees. Its market capitalization is roughly $107 million. In the fiscal year ended 2025-12-31, BDTX reported $70M in revenue and $22M in net income.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $70M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | $20M | ($79M) | ($86M) | ($93M) | — |
| Net Income | $22M | ($70M) | ($82M) | ($91M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $70M |
| Operating Income (EBIT) | ($11M) | ($10M) | ($11M) | ($13M) | $54M |
| Net Income | ($9M) | ($15M) | ($8M) | ($11M) | $56M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $143M | $123M | $159M | $156M | — |
| Total Liabilities | $31M | $39M | $42M | $41M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BDTX viewer.
About TickerBase · Data methodology & sources